Fulton Breakefield Broenniman LLC Acquires 14,641 Shares of Stryker Corporation $SYK

Fulton Breakefield Broenniman LLC lifted its holdings in shares of Stryker Corporation (NYSE:SYK) by 41.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 50,123 shares of the medical technology company’s stock after purchasing an additional 14,641 shares during the period. Stryker comprises about 1.1% of Fulton Breakefield Broenniman LLC’s investment portfolio, making the stock its 25th biggest position. Fulton Breakefield Broenniman LLC’s holdings in Stryker were worth $17,617,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Clayton Financial Group LLC bought a new position in shares of Stryker during the 3rd quarter valued at $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker during the 3rd quarter valued at $27,000. Howard Hughes Medical Institute bought a new position in shares of Stryker during the 2nd quarter valued at $29,000. Strive Asset Management LLC bought a new position in shares of Stryker during the 3rd quarter valued at $30,000. Finally, ANTIPODES PARTNERS Ltd bought a new position in shares of Stryker during the 3rd quarter valued at $34,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 5.90% of the company’s stock.

Stryker Trading Up 0.3%

NYSE:SYK opened at $332.40 on Tuesday. The company has a 50-day moving average price of $356.60 and a 200-day moving average price of $361.44. Stryker Corporation has a 12 month low of $319.32 and a 12 month high of $404.87. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The stock has a market cap of $127.30 billion, a price-to-earnings ratio of 39.57, a P/E/G ratio of 1.94 and a beta of 0.92.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. During the same period last year, the company posted $4.01 EPS. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. Equities analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is currently 41.90%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on SYK. BTIG Research increased their price target on shares of Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Friday, January 30th. William Blair reissued an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Jefferies Financial Group reissued a “buy” rating and set a $465.00 price target on shares of Stryker in a research report on Wednesday, March 4th. Robert W. Baird set a $437.00 price target on shares of Stryker in a research report on Friday, January 30th. Finally, Evercore set a $390.00 price target on shares of Stryker in a research report on Monday, January 5th. Fourteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $427.50.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.